Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF V600E Mutation”

134 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 134 results

Testing effectiveness (Phase 2)Study completedNCT01928940
What this trial is testing

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

Who this might be right for
Solid Tumours
GlaxoSmithKline 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT04526782
What this trial is testing

ENCOrafenib With Binimetinib in bRAF NSCLC

Who this might be right for
Non Small Cell Lung CancerBRAF V600E
Intergroupe Francophone de Cancerologie Thoracique 119
Testing effectiveness (Phase 2)Active Not RecruitingNCT03224767
What this trial is testing

Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

Who this might be right for
BRAF V600E Mutation PresentPapillary Craniopharyngioma
Alliance for Clinical Trials in Oncology 24
Large-scale testing (Phase 3)Study completedNCT01689519
What this trial is testing

A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 495
Testing effectiveness (Phase 2)WithdrawnNCT02672358
What this trial is testing

Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC

Who this might be right for
Non-Small-Cell Lung Cancer
Novartis Pharmaceuticals
Very early researchLooking for participantsNCT06610682
What this trial is testing

A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma

Who this might be right for
BRAF V600E Mutation
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 24
Testing effectiveness (Phase 2)Looking for participantsNCT06207656
What this trial is testing

Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer

Who this might be right for
Colorectal Cancer
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) 70
Testing effectiveness (Phase 2)Looking for participantsNCT05706779
What this trial is testing

Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer

Who this might be right for
Colorectal CancerBRAF V600E Mutation Positive
Federation Francophone de Cancerologie Digestive 30
Testing effectiveness (Phase 2)Ended earlyNCT02410863
What this trial is testing

Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma

Who this might be right for
Malignant Melanoma
Prof. Dr. med. Dirk Schadendorf 10
Large-scale testing (Phase 3)Looking for participantsNCT06008119
What this trial is testing

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer Metastatic
Shanghai Kechow Pharma, Inc. 165
Early research (Phase 1)Ended earlyNCT05743036
What this trial is testing

ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc 44
Early research (Phase 1)Looking for participantsNCT06902376
What this trial is testing

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

Who this might be right for
Anaplastic Thyroid CancerThyroid CancerBRAF Mutation-Related Tumors
UNC Lineberger Comprehensive Cancer Center 12
Post-approval studies (Phase 4)Not Yet RecruitingNCT07010393
What this trial is testing

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

Who this might be right for
Thyroid Neoplasms
Fujian Medical University 335
Post-approval studies (Phase 4)WithdrawnNCT07092410
What this trial is testing

Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib

Who this might be right for
Melanoma BRAF V600E/K Mutated
SRH Wald-Klinikum Gera GmbH
Testing effectiveness (Phase 2)Study completedNCT05510895
What this trial is testing

Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer

Who this might be right for
Colorectal CancerColon CancerBRAF V600E+2 more
AIO-Studien-gGmbH 2
Testing effectiveness (Phase 2)Ended earlyNCT01586195
What this trial is testing

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Who this might be right for
Malignant Melanoma
Genentech, Inc. 31
Not applicableLooking for participantsNCT06262919
What this trial is testing

Special Drug Use-results Surveillance of Tafinlar/Mekinist

Who this might be right for
BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
Novartis Pharmaceuticals 110
Early research (Phase 1)Ended earlyNCT02097225
What this trial is testing

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Who this might be right for
BRAF V600E Mutation PresentBRAF V600K Mutation PresentMetastatic Malignant Solid Neoplasm+7 more
National Cancer Institute (NCI) 22
Not applicableNot Yet RecruitingNCT05988697
What this trial is testing

Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib

Who this might be right for
NSCLCBRAF V600E MutationAdvanced Cancer+2 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 36
Testing effectiveness (Phase 2)Ended earlyNCT04534283
What this trial is testing

A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

Who this might be right for
CancerCancer MetastaticBRAF V600E+4 more
Anita Turk 16
Next Page